Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around

Description

Summary

Official Title

LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor

Details

Keywords

Solid Tumor, 177Lu-FAP-2286, 68Ga-FAP-2286, Theranostic, FAP-2286, Fibroblast Activation Protein (FAP), Dosimetry, cancer-associated fibroblasts (CAF), Peptide-Targeted Radioligand Therapy (PTRT), Peptide Receptor Radionuclide Therapy (PRRT), Targeted radioligand therapy (TRT), Targeted radionuclide therapy, Lutetium-177, Gallium-68, Neoplasms, Specific Solid Tumors

Eligibility

Locations

  • UCSF Medical Center accepting new patients
    San Francisco California 94158 United States
  • Hoag Hospital Irvine accepting new patients
    Irvine California 92618 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Novartis Pharmaceuticals
ID
NCT04939610
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 222 study participants
Last Updated